Grail Grail Launches Galleri Cancer Early Detection Test, Backed by First PATHFINDER Interventional Data Premium The company presented its first analyses answering crucial questions about real-world performance and impact on patients' well-being and healthcare utilization. Illumina Challenges European Commission's Jurisdiction Over Review of Grail Acquisition in EU General Court Illumina continues to fight against European regulators who want the European Commission to review the deal under untested legal mechanisms. European Union to Review Illumina's Planned Grail Acquisition Under New Guidance Illumina reaffirmed its commitment to the $8 billion deal and said it does not believe the European authorities have jurisdiction to review it. Grail Cancer Early Detection Test Performance Holds Steady as Q2 Launch Approaches Premium Recent results from the firm's case-control study cohort showed overall sensitivity of about 50 percent but higher performance for a subset of high-mortality cancers. Illumina Parries FTC Challenge to Grail Acquisition With Deals for Competing Customers Premium The US Federal Trade Commission's recent challenge raises the question who Illumina can acquire while remaining a quasi-monopolist for sequencing equipment. Mar 31, 2021 Illumina Upgraded to Buy by Canaccord Genuity Mar 30, 2021 FTC Moves to Block Illumina's $8B Grail Acquisition Feb 23, 2021 Grail Signs on Quest Diagnostics to Provide Phlebotomy for Cancer Detection Test Jan 11, 2021 Multi-Cancer Molecular Screening Assays Primed for Clinical Implementation in 2021 Premium Jan 11, 2021 Grail Inks Deals With Amgen, AstraZeneca, Bristol Myers Squibb for MRD Test Development Dec 28, 2020 M&A Deals in MDx/Omics Research Tools Space Fall 13 Percent in 2020 Premium Dec 22, 2020 Illumina Upgraded to Overweight by Piper Sandler Nov 30, 2020 Grail Inks Deal With UK National Health Service to Offer Cancer Screening Blood Test in 2021 Sep 24, 2020 Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test Sep 22, 2020 UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal Sep 21, 2020 Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider Premium Sep 21, 2020 JP Morgan Downgrades Illumina to Neutral on Grail Deal Sep 21, 2020 Illumina to Acquire Grail for $8B in Cash and Stock Sep 16, 2020 Illumina's Stock Falls 9 Percent on Grail Acquisition Rumors Sep 14, 2020 Grail Plans Additional Liquid Biopsy Tests for Cancer Detection, Monitoring Premium Sep 9, 2020 Early Cancer Detection Firm Grail Files for IPO May 8, 2020 People in the News: Mostafa Ronaghi, Stephen Moore, Alex Aravanis, More May 6, 2020 Grail Raises $390M in Series D Financing May 1, 2020 People in the News: Peter Meintjes, Timothy Chan, Satnam Alag, More Apr 29, 2020 Pan-Cancer Screening Tests Report First Performance Numbers in Undiagnosed Cohorts Premium Load More Breaking News Sequencing Study Uncovers MERS-Related Coronavirus in Swiss Bats Angstrom Bio Raises $3M in Private Financing Eagle Biosciences, Genetic Analysis Ink Distribution Agreement for Gut Microbiota Test Centogene Q1 Revenues Grow More Than Fivefold Driven by COVID-19 Testing Epizyme Partnering With Quest Diagnostics for Lymphoma Mutation Testing Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel The Scan CDC Calls Delta "Variant of Concern" CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern." From FDA to Venture Capital Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post. Consent Questions Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles. Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.